Telomir Pharmaceuticals, Inc.: stockholders equity

What this measure means

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Exact concept: us-gaap:StockholdersEquity. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2021-12-31 to 2025-12-31. The SEC response was captured on 2026-09-21.

Selected filing history

Related financial histories

• Telomir Pharmaceuticals, Inc.: total assets
• Telomir Pharmaceuticals, Inc.: total liabilities
• Telomir Pharmaceuticals, Inc.: net income or loss
• Telomir Pharmaceuticals, Inc.: operating cash flow
• Telomir Pharmaceuticals, Inc.: financing cash flow
• Telomir Pharmaceuticals, Inc.: retained earnings or deficit
• Telomir Pharmaceuticals, Inc.: basic weighted-average shares
• Telomir Pharmaceuticals, Inc.: diluted weighted-average shares
• Telomir Pharmaceuticals, Inc.: basic earnings per share
• Telomir Pharmaceuticals, Inc.: diluted earnings per share
• Telomir Pharmaceuticals, Inc.: current assets
• Telomir Pharmaceuticals, Inc.: current liabilities
• Telomir Pharmaceuticals, Inc.: operating expenses
• Telomir Pharmaceuticals, Inc.: research and development expense

Inspect the source

Entity

Telomir Pharmaceuticals, Inc. / CIK 0001971532

Captured

2026-09-21T17:36:59.180Z

SEC response SHA-256

2bf53a6ee4392d72c55462c84b1ae1101543d1b4cd3306c9906ab52eae14a73f

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

• Get an API key and run your first validation
• Connect the MCP server to your coding assistant
• Inspect the ALPHAC engine on GitHub
• Read the MCP server source and integration examples

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001971532.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))